

OFFICE OF THE SECRETARY OF STATE

LAVONNE GRIFFIN-VALADE
SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE
AND TRIBAL LIAISON



ARCHIVES DIVISION

STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

PERMANENT ADMINISTRATIVE ORDER

BP 54-2024

CHAPTER 855
BOARD OF PHARMACY

FILED

06/18/2024 8:47 AM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Adds CGM to formulary, adds STI prevention and short-acting opioid antagonists protocols, repeals pseudoephedrine

EFFECTIVE DATE: 06/20/2024

AGENCY APPROVED DATE: 06/13/2024

CONTACT: Rachel Melvin

971-673-0001

pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150

Portland, OR 97232

Filed By:

Rachel Melvin

Rules Coordinator

RULES:

855-115-0340, 855-115-0345

AMEND: 855-115-0340

NOTICE FILED DATE: 04/17/2024

RULE SUMMARY: Amends rule by adding continuous glucose monitors and associated supplies to the formulary compendium.

CHANGES TO RULE:

855-115-0340

Services: Prescribing - Formulary Compendium

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, a FDA-approved drug and device listed in the following compendium, pursuant to a diagnosis by a health care practitioner who has prescriptive authority and who is qualified to make the diagnosis. The diagnosis must be documented. Devices and supplies:¶

- (1) Diabetic blood sugar testing supplies;¶
- (2) Injection supplies;¶
- (3) Nebulizers and associated supplies;¶
- (4) Inhalation spacers;¶
- (5) Peak flow meters;¶
- (6) International Normalized Ratio (INR) testing supplies;¶
- (7) Enteral nutrition supplies; ¶
- (8) Ostomy products and supplies; and¶
- (9) Non-invasive blood pressure monitors; and ¶
- (10) Continuous glucose monitors and associated supplies.

Statutory/Other Authority: ORS 689.205

Statutes/Other Implemented: ORS 689.645, ORS 689.649

AMEND: 855-115-0345

REPEAL: Temporary 855-115-0345 from BP 25-2024

NOTICE FILED DATE: 04/17/2024

RULE SUMMARY: Repeals pseudoephedrine protocol from the protocol compendium. ORS 475.005(6),(17) and ORS 475.185 prohibit a pharmacist from prescribing a controlled substance. Controlled substances include those scheduled by the board under ORS 475.035. Pseudoephedrine is scheduled by the board as a schedule V controlled substance under ORS 475.035 in OAR 855-080-0026 in accordance with ORS 475.973.

CHANGES TO RULE:

855-115-0345

Services: Prescribing - Protocol Compendium

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices listed in the following compendium, pursuant to a statewide drug therapy management protocol. ¶

(1) Continuation of therapy including emergency refills of insulin (v. 06/20234)¶

(2) Conditions¶

(a) Cough and cold symptom management¶

(A) Pseudoephedrine (v. 06/2021);¶

~~(B) Benzonatate (v. 06/2021);¶~~

~~(C) Short-acting beta agonists (v. 06/2021);¶~~

~~(D) Intranasal corticosteroids (v. 06/2021);¶~~

(b) Vulvovaginal candidiasis (VVC) (v. 06/2021);¶

(c) COVID-19 Antigen Self-Test (v. 12/2021);¶

(3) Preventative care¶

(a) Emergency Contraception (v. 06/2021);¶

(b) Male and female condoms (v. 06/2021);¶

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/20224);¶

(d) Travel Medications (v. 06/20234);¶

(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);¶

(f) HIV Pre-exposure Prophylaxis (PrEP) (v.06/2023); and¶

(g) Contraception (v. 06/2023);¶

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);¶

(i) Short-acting Opioid Antagonists (v. 06/2024); and¶

(j) Vaccines:¶

(A) Standard Protocol for All Vaccines: Cover Page & Assessment and Treatment Care Pathway (v. 06/2024); ¶

(B) Standard Protocol for All Vaccines: Managing Adverse Reactions (v. 06/2024); ¶

(C) Cholera (v. 02/2024); ¶

(D) Coronavirus 2019 (v. 06/2024); ¶

(E) Haemophilus Influenza type b (v. 06/2024);¶

(F) Hepatitis A containing vaccines (v. 02/2024); ¶

(G) Hepatitis B containing vaccines (v. 02/2024); ¶

(H) Human Papillomavirus (v. 02/2024); ¶

(I) Influenza - Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 2023-24 (v. 06/2024); ¶

(J) Influenza - Live Attenuated Influenza Vaccine 2023-24 (v. 02/2024); ¶

(K) Japanese Encephalitis (v. 06/2024); ¶

(L) Meningococcal containing vaccines (v. 06/2024); ¶

(M) Measles Mumps & Rubella containing vaccines (v. 02/2024); ¶

(N) Pneumococcal (v. 06/2024); ¶

(O) Polio (v. 06/2024);¶

¶

(P) Rabies (v. 02/2024); ¶

(Q) Respiratory Syncytial Virus (v. 06/2024);¶

(R) Tetanus Diphtheria containing vaccines (v. 06/2024);¶

(S) Typhoid (v. 02/2024); ¶

(T) Varicella containing vaccines (v. 02/2024);¶

(U) Yellow fever (v. 06/2024); and¶

(V) Zoster (v. 02/2024).¶

[Publications: Publications referenced are available from the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689